5,947 Shares in RxSight, Inc. (NASDAQ:RXST) Purchased by Sherbrooke Park Advisers LLC

Sherbrooke Park Advisers LLC purchased a new position in RxSight, Inc. (NASDAQ:RXST) in the fourth quarter, Holdings Channel reports. The fund purchased 5,947 shares of the company’s stock, valued at approximately $204,000.

A number of other large investors also recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in RxSight by 4.2% in the 4th quarter. Vanguard Group Inc. now owns 2,383,548 shares of the company’s stock worth $81,946,000 after purchasing an additional 96,464 shares during the period. Bank of America Corp DE raised its holdings in RxSight by 23.7% in the 4th quarter. Bank of America Corp DE now owns 2,159,923 shares of the company’s stock worth $74,258,000 after purchasing an additional 413,737 shares during the period. Artisan Partners Limited Partnership raised its holdings in RxSight by 32.6% in the 4th quarter. Artisan Partners Limited Partnership now owns 1,551,620 shares of the company’s stock worth $53,345,000 after purchasing an additional 381,389 shares during the period. Geode Capital Management LLC raised its holdings in RxSight by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 830,758 shares of the company’s stock worth $28,568,000 after purchasing an additional 13,641 shares during the period. Finally, Deutsche Bank AG raised its holdings in RxSight by 1.6% in the 4th quarter. Deutsche Bank AG now owns 657,224 shares of the company’s stock worth $22,595,000 after purchasing an additional 10,634 shares during the period. Institutional investors and hedge funds own 78.78% of the company’s stock.

Insider Activity at RxSight

In related news, Director Tamara Fountain sold 7,000 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $25.71, for a total value of $179,970.00. Following the completion of the sale, the director now owns 24,793 shares of the company’s stock, valued at approximately $637,428.03. This trade represents a 22.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 9.36% of the company’s stock.

RxSight Stock Performance

NASDAQ:RXST opened at $16.62 on Wednesday. RxSight, Inc. has a one year low of $12.53 and a one year high of $64.50. The stock has a market cap of $675.39 million, a PE ratio of -20.02 and a beta of 1.32. The stock has a 50 day moving average price of $17.72 and a 200 day moving average price of $29.62.

RxSight (NASDAQ:RXST) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. The firm had revenue of $37.90 million during the quarter, compared to analysts’ expectations of $38.74 million. During the same quarter last year, the firm earned ($0.25) earnings per share. The business’s revenue for the quarter was up 28.5% on a year-over-year basis. As a group, analysts predict that RxSight, Inc. will post -0.7 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on RXST shares. Piper Sandler started coverage on RxSight in a report on Tuesday, April 15th. They issued a “neutral” rating and a $18.00 price target for the company. UBS Group cut RxSight from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $45.00 to $16.00 in a report on Wednesday, April 9th. Bank of America reissued an “underperform” rating and set a $22.00 target price (down previously from $36.00) on shares of RxSight in a report on Thursday, April 3rd. Wells Fargo & Company raised RxSight from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $17.00 to $25.00 in a report on Monday. Finally, JPMorgan Chase & Co. reissued an “underweight” rating and set a $17.00 target price (down previously from $40.00) on shares of RxSight in a report on Friday, April 4th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $37.90.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.